Lifeward presented new longitudinal safety data for its ReWalk Personal Exoskeleton at the American Spinal Injury Association (ASIA) 2026 Annual Scientific Meeting in San Antonio, Texas, held April 24‑26 2026. The data were announced on May 4 2026.
The poster, titled “Prevalence, Location, and Other Data Regarding Lower Extremity Fractures during Clinical Application of the ReWalk Exoskeleton 2013‑2025,” shows a 3 % lifetime fracture prevalence across the 2013‑2025 period, a drop to 0.3 % over the past six years, and zero fractures among 97 German users since 2018. It also notes that 87 % of fracture events occurred between 2014 and 2019, indicating a steep decline in early‑stage usage.
The improved safety profile is a key driver for expanding ReWalk’s market penetration, especially under the new Medicare reimbursement framework that began in 2024. Mark Grant, CEO, said the data “are an important milestone … reflecting our commitment to continued advancements in device technology, combined with refined patient and provider training, translating directly into better outcomes for patients.” The zero‑fracture record in Germany underscores the device’s reliability when used with proper training and monitoring.
Lifeward’s presentation comes at a time when the company is solidifying payer coverage, having secured prior‑authorization approvals from major Medicare Advantage plans and finalizing Medicare benefit category assignment. The safety data reinforce confidence among clinicians, payers, and patients, positioning ReWalk to capture a larger share of the growing exoskeleton market and to capitalize on the expanding reimbursement landscape.
The data also provide a competitive edge over peers such as Ekso Bionics and CYBERDYNE, as Lifeward’s decade‑long real‑world evidence base is unique in the industry. By demonstrating a consistent decline in adverse events, Lifeward strengthens its case for broader adoption and may accelerate the rollout of future iterations of the ReWalk platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.